MIRMMirum Pharmaceuticals, Inc.

96.31USD-5.80%Mkt Cap: 5.87B $P/E:

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat…

Key Statistics

Company
Market Cap5.87B $
Enterprise Value6.63B $
Revenue (TTM)618.07M $
Gross Profit421.07M $
Net Income (TTM)-23.36M $
Revenue/Share11.02 USD
Last Price96.31 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees433
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS6047491013
Valuation
P/E (Trailing)
P/E (Forward)-280.01
PEG
EV/EBITDA-94.30
EV/Revenue10.72
P/S9.58
P/B-602.92
EPS (TTM)-13.38
EPS (Forward)-0.35
52W Range
63.2350% of range130.00
52W High130.00 USD
52W Low63.23 USD
Profitability
Gross Margin80.77%
Oper. Margin-14.81%
EBITDA Margin-11.37%
Profit Margin-4.48%
ROE-7.42%
ROA-2.77%
Growth
Revenue Growth37.90%
Earnings Growth
Cash Flow & Leverage
Operating CF55.83M $
CapEx (TTM)954.00K $
FCF Margin12.40%
FCF Yield1.30%
Net Debt324.66M $
Net Debt/EBITDA-4.62
Balance Sheet
Debt/Equity1.02
Current Ratio2.86
Quick Ratio2.62
Book Value/Sh-0.1610 USD
Cash/Share6.750 USD
Dividends
Fwd Div Rate
Trail. Div Rate0.0000 USD
Div. Yield
5Y Avg Yield
Payout Ratio0.00%
Ex-Div Date
Pay Date
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)138.21 USD
Upside (mean)+43.5%
Target Range118.00 USD183.00 USD
$118.00+43.5% to mean$183.00
# Analysts14
Ownership
Shares Out.60.98M
Float56.42M
Insiders1.29%
Institutions111.94%
Short Interest
Short Ratio10.5d
Short % Float14.68%
Short % Out.11.19%
Shares Short6.82M
Short (prev mo.)7.48M
Technical
SMA 50110.48 (-12.8%)
SMA 20094.50 (+1.9%)
Beta0.51
S&P 52W Chg18.16%
Avg Vol (30d)659.56K
Avg Vol (10d)602.05K
Technical Indicators
RSI (14)37.9
MACD-3.7953
MACD Signal-3.4384
MACD Hist.-0.3570
BB Upper116.87 USD
BB Middle104.15 USD
BB Lower91.44 USD
BB Width24.42%
ATR (14)4.977 USD
Vol Ratio (20d)0.93x